AbbVie (ABBV) Receivables (2012 - 2026)

AbbVie (ABBV) has 15 years of Receivables data on file, last reported at $12.5 billion in Q1 2026.

• Receivables for Q1 2026 came in at $12.5 billion, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.5 billion (changed 0.02% YoY), and the FY2025 annual result was $12.6 billion, up 15.29% from the prior year.
• Receivables retreated to $12.5 billion in Q1 2026 per ABBV's latest filing, from $12.6 billion in the prior quarter.
• Over five years, Receivables peaked at $12.8 billion in Q3 2025 and troughed at $10.7 billion in Q1 2022.
• A 5-year average of $11.7 billion and a median of $11.5 billion in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables increased 15.75% in 2022, then decreased 2.12% in 2024.
• A 5-year view of Receivables shows it stood at $11.3 billion in 2022, then fell by 0.88% to $11.2 billion in 2023, then slipped by 2.12% to $10.9 billion in 2024, then climbed by 15.29% to $12.6 billion in 2025, then decreased by 0.87% to $12.5 billion in 2026.
• Business Quant data shows ABBV's Receivables at $12.5 billion in Q1 2026, $12.6 billion in Q4 2025, and $12.8 billion in Q3 2025.